Introduction:
SCG Cell Therapy and the Agency for Science, Technology and Research (A*STAR) have partnered to establish joint laboratories to advance the development of induced pluripotent stem cell (iPSC) technology for the production of cellular immunotherapies that meet Good Manufacturing Practice (GMP) standards. This collaboration aims to accelerate the translation of iPSC research into clinically viable therapies and strengthen Singapore’s position as a global leader in cell therapy innovation.
- SCG Cell Therapy and A*STAR have launched joint laboratories to develop iPSC technology for scalable GMP manufacturing of cell therapies.
- The collaboration aims to produce novel cell therapies that meet GMP standards and offer hope for patients with serious illnesses.
- SCG contributes its specialized, automated cell therapy manufacturing technologies, while A*STAR brings its monoclonal antibody assets, iPSC banks, and expertise in process scaling and analytics.
- The joint laboratories will advance iPSC technology for scalable, GMP-compliant cell therapy production and serve as a platform for nurturing talent in the field.
- Through this collaboration, Singapore aims to become a global leader in the development and manufacturing of cell therapies.
Conclusion:
The partnership between SCG Cell Therapy and A*STAR in Singapore aims to leverage iPSC technology and GMP manufacturing capabilities to produce novel cell therapies that meet the highest quality standards. This collaboration brings together expertise from both organizations and has the potential to revolutionize regenerative medicine and provide new treatment options for patients with serious illnesses. The joint laboratories will also contribute to the development of talent in the field and strengthen Singapore’s position as a global leader in cell therapy innovation.
